Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993)

• Published in: The Journal of the American Animal Hospital Association Vol. 34; no. 5; p. 417
• Main Authors: Wood, C.A. (University of Minnesota, St. Paul, MN.), Moore, A.S, Gliatto, J.M, Ablin, L.A, Berg, R.J, Rand, W.M
• Format: Journal Article
• Language: English
• Published: United States 01.09.1998
• Subjects: Animals; BAZO; CHIEN; Dog Diseases - mortality; Dog Diseases - surgery; DOGS; DRUG THERAPY; DURACION; DURATION; DUREE; ESPLENECTOMIA; Female; Follow-Up Studies; Hemangiosarcoma - mortality; Hemangiosarcoma - surgery; Hemangiosarcoma - veterinary; Male; PATHOGENESE; PATHOGENESIS; PATOGENESIS; PERRO; Prognosis; RATE; Retrospective Studies; SARCOMA; SARCOME; SPLEEN; SPLENECTOMIE; SPLENECTOMY; Splenectomy - veterinary; Splenic Neoplasms - mortality; Splenic Neoplasms - surgery; Splenic Neoplasms - veterinary; SUPERVIVENCIA; SURVIE; SURVIVAL; Survival Analysis; Survival Rate; TERAPEUTICA MEDICAMENTOSA; THERAPEUTIQUE MEDICAMENTEUSE; Time Factors
• ISSN: 0587-2871; 1547-3317
• DOI: 10.5326/15473317-34-5-417

A retrospective analysis was performed on the case records of 32 dogs with Stage I or II splenic hemangiosarcoma that were treated by splenectomy alone and that survived the seven-day postoperative period. Median survival time for these 32 cases was 86 days (mean, 116 days; range, 14 to 470 days), and the one-year survival rate was estimated to be 6.25%. Survival was not influenced by signalment, presenting signs, stage of disease, or clinicopathological findings. The data provides a basis from which to evaluate adjuvant chemotherapy for splenic hemangiosarcoma that is confined to the spleen macroscopically.